AGP
Artia Global Partners Portfolio holdings
AUM
$389M
This Quarter Return
+10%
1 Year Return
+34.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$253M
AUM Growth
+$253M
(+5.1%)
Cap. Flow
-$2.29M
Cap. Flow
% of AUM
-0.9%
Top 10 Holdings %
Top 10 Hldgs %
90%
Holding
36
New
8
Increased
2
Reduced
3
Closed
8
Top Buys
| 1 |
Eli Lilly
LLY
|
$38.7M |
| 2 |
Novo Nordisk
NVO
|
$4.11M |
| 3 |
Cytokinetics
CYTK
|
$2.68M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$2.6M |
| 5 |
Insmed
INSM
|
$2.32M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$10.9M |
| 2 |
Roivant Sciences
ROIV
|
$10.7M |
| 3 |
89bio
ETNB
|
$7.19M |
| 4 |
Sarepta Therapeutics
SRPT
|
$6.93M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$6.37M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
GRTS
26
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $194K | 0.06% |
95,170
| – | – |
|
27
Tyra Biosciences
TYRA
$675M
| $142K | 0.04% |
10,253
-35,000
| -77% | -$485K |
|
28
Alnylam Pharmaceuticals
ALNY
$58.5B
| – | – |
-15,971
| Closed | -$2.83M |
|
|
29
89bio
ETNB
$1.34B
| – | – |
-465,465
| Closed | -$7.19M |
|
30
Structure Therapeutics
GPCR
$1.11B
| – | – |
0
| – | – |
|
|
31
Roivant Sciences
ROIV
$8.15B
| – | – |
-914,023
| Closed | -$10.7M |
|
|
32
Sarepta Therapeutics
SRPT
$1.78B
| – | – |
-57,162
| Closed | -$6.93M |
|
33
Thermo Fisher Scientific
TMO
$186B
| – | – |
-2,109
| Closed | -$1.07M |
|
|
34
Vertex Pharmaceuticals
VRTX
$100B
| – | – |
-18,314
| Closed | -$6.37M |
|
|
CBAY
35
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-41,261
| Closed | -$615K |
|
|
SGEN
36
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
-51,175
| Closed | -$10.9M |
|